Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson’s Disease

• Main Authors: Stewart F. Graham, Nolwen L. Rey, Zafer Ugur, Ali Yilmaz, Eric Sherman, Michael Maddens, Ray O. Bahado-Singh, Katelyn Becker, Emily Schulz, Lindsay K. Meyerdirk, Jennifer A. Steiner, Jiyan Ma, Patrik Brundin
• Format: Article
• Language: English
• Published: MDPI AG 2018-10-01
• Series: Metabolites
• Subjects: prodromal Parkinson’s disease; bile acids; mass spectrometry; biomarkers; α-synuclein aggregates
• Online Access: https://www.mdpi.com/2218-1989/8/4/71

For people with Parkinson&#8217;s disease (PD), considered the most common neurodegenerative disease behind Alzheimer&#8217;s disease, accurate diagnosis is dependent on many factors; however, misdiagnosis is extremely common in the prodromal phases of the disease, when treatment is thought to be most effective. Currently, there are no robust biomarkers that aid in the early diagnosis of PD. Following previously reported work by our group, we accurately measured the concentrations of 18 bile acids in the serum of a prodromal mouse model of PD. We identified three bile acids at significantly different concentrations (<i>p</i> &lt; 0.05) when mice representing a prodromal PD model were compared with controls. These include &#969;-murichoclic acid (MCAo), tauroursodeoxycholic acid (TUDCA) and ursodeoxycholic acid (UDCA). All were down-regulated in prodromal PD mice with TUDCA and UDCA at significantly lower levels (17-fold and 14-fold decrease, respectively). Using the concentration of three bile acids combined with logistic regression, we can discriminate between prodromal PD mice from control mice with high accuracy (AUC (95% CI) = 0.906 (0.777&#8315;1.000)) following cross validation. Our study highlights the need to investigate bile acids as potential biomarkers that predict PD and possibly reflect the progression of manifest PD.